Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder.
Humans
Receptors, Estrogen
/ metabolism
Receptors, Androgen
/ metabolism
Androgens
/ metabolism
Urinary Bladder
Estrogen Receptor alpha
/ metabolism
Estrogen Receptor beta
/ metabolism
Retrospective Studies
Prognosis
Urinary Bladder Neoplasms
/ pathology
Carcinoma, Transitional Cell
/ pathology
Estrogens
Androgen receptor
Estrogen receptor alpha
Estrogen receptor beta
Urinary bladder cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
14
07
2023
accepted:
25
08
2023
medline:
2
11
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
The molecular mapping of cancers by the Cancer Genome Atlas Project has accelerated the quest for new therapeutic targets for urinary bladder cancer, including sex steroid receptors. Previous studies have demonstrated conflicting results on their relationship with bladder cancer, and there is sparse data on their expression in the Indian population. The aim of our study is to examine the expression of androgen receptors (AR) and estrogen receptors (ERα and ERβ) in patients with bladder cancer and their correlation with clinicopathologic features. In this retrospective cohort study, a total of 132 patients, who were surgically managed for urinary bladder mass by transurethral resection or radical cystectomy in our institute, with transitional cell carcinoma on histopathology and with at least two years of follow-up were included. Their demographic and treatment details were obtained, histopathology blocks were retrieved and immunohistochemical staining for androgen and estrogen receptors was performed. Then, the relationship between their expression and clinicopathologic features was studied. A total of 3.79% of patients showed estrogen receptor alpha positivity, 51.52% estrogen receptor beta positivity and 63.64% androgen receptor positivity. No statistically significant correlation was found between age of patients (p = 0.75/0.52/0.87), tumour stage and grade (0.71/0.3/0.21), pathological variant (p = 1/0.58/0.38) and overall survival (p = 0.70/0.052/0.45 for NMIBC and p = 0.82/0.36/0.22) and estrogen receptor alpha, estrogen receptor beta and androgen receptor-positive status, respectively. Estrogen receptor beta positivity was significantly higher in patients with unifocal (p = 0.015) and small tumours (< 5 cm) (p = 0.03), and its expression was associated with better disease-free survival (DFS) (p = 0.046) in patients of non-muscle invasive bladder cancer (NMIBC). Our study has the largest sample size conducted on Indian population with results differing from previous studies conducted on western population. Estrogen receptor beta expression was significantly associated with small unifocal tumours and better DFS. Estrogen receptor alpha and androgen receptor expression were not found to be associated with the clinicopathologic features of the study population.
Identifiants
pubmed: 37668795
doi: 10.1007/s00432-023-05348-z
pii: 10.1007/s00432-023-05348-z
doi:
Substances chimiques
Receptors, Estrogen
0
Receptors, Androgen
0
Androgens
0
Estrogen Receptor alpha
0
Estrogen Receptor beta
0
Estrogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15795-15804Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
An MH, Kim MS, Kim C, Noh TI, Joo KJ, Lee DH, Yi KH, Kwak JW, Hwang TH, Park RW, Kang SH (2023) Association of 5α-reductase inhibitor prescription with bladder cancer progression in males in South Korea. JAMA Netw Open 6(5):e2313667
doi: 10.1001/jamanetworkopen.2023.13667
pubmed: 37191958
pmcid: 10189569
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75–94
doi: 10.1016/j.eururo.2021.08.010
pubmed: 34511303
Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026
doi: 10.1056/NEJMoa1613683
pubmed: 28212060
pmcid: 5635424
Bolenz C, Lotan Y, Ashfaq R, Shariat SF (2009) Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 56(6):1093–1095
doi: 10.1016/j.eururo.2009.06.032
pubmed: 19596509
Boorjian S, Ugras S, Mongan NP et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64(2):383–388
doi: 10.1016/j.urology.2004.03.025
pubmed: 15302512
Deltourbe L, Lacerda Mariano L, Hreha TN, Hunstad DA, Ingersoll MA (2022) The impact of biological sex on diseases of the urinary tract. Mucosal Immunol 15(5):857–866
doi: 10.1038/s41385-022-00549-0
pubmed: 35869147
pmcid: 9305688
Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A (2009) Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol 25:207–210
doi: 10.4103/0970-1591.52916
pubmed: 19672348
pmcid: 2710066
Gupta S, Dhillon J, Magliocco AM, Puskas J, Caceres G, Masawi F, Doronin Y, Zhang J (2019) Results from a phase i/ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mbc). J Clin Oncol 37:471
doi: 10.1200/JCO.2019.37.7_suppl.471
Ide H, Inoue S, Miyamoto H (2017) Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies. PLoS ONE 12:e0174746
doi: 10.1371/journal.pone.0174746
pubmed: 28362839
pmcid: 5375178
Mashhadi R, Pourmand G, Kosari F et al (2014) Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J 11(6):1968–1973
pubmed: 25433476
Mir C, Shariat SF, van der Kwast TH et al (2011) Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 108(1):24–30
doi: 10.1111/j.1464-410X.2010.09834.x
pubmed: 21070579
Miyamoto H, Yao JL, Chaux A et al (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109(11):1716–1726
doi: 10.1111/j.1464-410X.2011.10706.x
pubmed: 22221549
Moorthy HK, Prabhu GG, Venugopal P (2020) Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol 36:171–178
doi: 10.4103/iju.IJU_320_19
pubmed: 33082631
pmcid: 7531383
Nam JK, Park SW, Lee SD, Chung MK (2014) Prognostic value of sex hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J 55:1214–1221
doi: 10.3349/ymj.2014.55.5.1214
pubmed: 25048477
pmcid: 4108804
Pachauri A, Pahwa HS, Kumar A (2017) Evaluation of androgen receptor and HER2/neu receptor in tumor tissue of transitional cell carcinoma of urinary bladder and normal bladder mucosa. Arch Int Surg 7:115–120
doi: 10.4103/ais.ais_5_18
Rodriguez-Vida A, Lerner SP, Bellmunt J (2018) The cancer genome atlas project in bladder cancer. Cancer Treat Res 175:259–271
doi: 10.1007/978-3-319-93339-9_12
pubmed: 30168126
Sankhwar M, Sankhwar SN, Bansal SK, Gupta G, Rajender S (2016) Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses. Sci Rep 1(6):27018
doi: 10.1038/srep27018
Scosyrev E, Trivedi D, Messing E (2010) Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol 20:404–408
doi: 10.1097/MOU.0b013e32833c7a9b
pubmed: 20592613
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30
doi: 10.3322/caac.21332
pubmed: 26742998
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Tripathi A, Gupta S (2020) Androgen receptor in bladder cancer: a promising therapeutic target. Asian J Urol 7(3):284–290
doi: 10.1016/j.ajur.2020.05.011
pubmed: 32742928
pmcid: 7385521
Tuygun C, Kankaya D, Imamoglu A et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29(1):43–51
doi: 10.1016/j.urolonc.2009.01.033
pubmed: 19372057
Wagih M, Kamel M (2020) Evaluation of androgen receptor status in urothelial carcinoma of the urinary bladder in Egyptian patients: an immunohistochemical study. Afr J Urol 26(1):1
doi: 10.1186/s12301-019-0014-1
Yuvaraja TB, Waigankar S, Bakshi G, Prakash G (2016) Genitourinary cancers: summary of Indian data. South Asian J Cancer. 5(3):122–124
doi: 10.4103/2278-330X.187577
pubmed: 27606296
pmcid: 4991131